SS
CRXT

Steve Schonfeld’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Steve Schonfeld’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,800
Closed -$51K – 3109
2021
Q4 		$51K Buy
+20,800
New +$90.3K ﹤0.01% 1947
2021
Q3 		– Sell
-30,000
Closed -$302K – 2629
2021
Q2 		$302K Buy
30,000
+19,026
+173% +$192K ﹤0.01% 1470
2021
Q1 		$111K Buy
+10,974
New +$111K ﹤0.01% 1621

Other funds holding CRXT

BCL
Bracebridge Capital LLC Boston, Massachusetts $5.53B AUM 25.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Steve Schonfeld's CRXT Position: Q1 2022 in Review

Steve Schonfeld sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q1 2022, closing a stake of 20,800 shares — an estimated $51K sold.

Steve Schonfeld first reported a position in CRXT in Q1 2021 and held it in 3 quarters. The position peaked at $302K in Q2 2021. 13 funds tracked by Wall St. Rank hold CRXT as of Q1 2022.

  • Steve Schonfeld reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Steve Schonfeld sold 20,800 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q1 2022, an estimated $51K.
  • Steve Schonfeld first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Steve Schonfeld's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $302K in Q2 2021.
  • 13 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q1 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2022, filed 16 May 2022.